Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine

Medical Hypotheses

Volumn 78, Issue 5, 2012, Pages 601-605

  Brietzke, Elisa ^a   Mansur, Rodrigo B ^a   Grassi Oliveira, Rodrigo ^b   Soczynska, Joanna K ^c,d   McIntyre, Roger S ^c,d,e  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LAMOTRIGINE; LITHIUM; QUETIAPINE; TOPIRAMATE; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID;

ARTICLE; BIPOLAR DISORDER; COMORBIDITY; DNA POLYMORPHISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; GENETIC SUSCEPTIBILITY; HUMAN; INFLAMMATION; MIGRAINE; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY;

BIPOLAR DISORDER; COMORBIDITY; CYTOKINES; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; MIGRAINE DISORDERS;

EID: 84859266814     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.01.036     Document Type: Article

References (89)

1. Ketter T.A. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry 2010, 71(6):e14.
2. Kapczinski F., Dias V.V., Kauer-Sant'anna M., et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009, 9(7):957-966.
3. Goldstein B.I., Kemp D.E., Soczynska J.K., Mcintyre R.S. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009, 70(8):1078-1090.
4. Haut S.R., Bigal M.E., Lipton R.B. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol 2006, 5(2):148-157.
5. Silberstein S.D. Migraine. Lancet 2004, 363(9406):381-391.
6. Lipton R.B., Bigal M.E. The epidemiology of migraine. Am J Med 2005, 118(Suppl. 1):3S-10S.
7. Dilsaver S.C., Benazzi F., Oedegaard K.J., Fasmer O.B., Akiskal H.S. Is a family history of bipolar disorder a risk factor for migraine among affectively ill patients?. Psychopathology 2009, 42(2):119-123.
8. Mcintyre R.S., Konarski J.Z., Wilkins K., Bouffard B., Soczynska J.K., Kennedy S.H. The prevalence and impact of migraine headache in bipolar disorder: results from the Canadian Community Health Survey. Headache 2006, 46(6):973-982.
9. Oedegaard K.J., Fasmer O.B. Is migraine in unipolar depressed patients a bipolar spectrum trait?. J Affect Disord 2005, 84(2-3):233-242.
10. Hirschfeld R.M., Calabrese J.R., Weissman M.M., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003, 64(1):53-59.
11. Low N.C., Du Fort G.G., Cervantes P. Prevalence, clinical correlates, and treatment of migraine in bipolar disorder. Headache 2003, 43(9):940-949.
12. Fasmer O.B. The prevalence of migraine in patients with bipolar and unipolar affective disorders. Cephalalgia 2001, 21(9):894-899.
13. Mahmood T., Romans S., Silverstone T. Prevalence of migraine in bipolar disorder. J Affect Disord 1999, 52(1-3):239-241.
14. Breslau N., Davis G.C. Migraine, physical health and psychiatric disorder: a prospective epidemiologic study in young adults. J Psychiatr Res 1993, 27(2):211-221.
15. Merikangas K.R., Angst J., Isler H. Migraine and psychopathology. Results of the Zurich cohort study of young adults. Arch Gen Psychiatry 1990, 47(9):849-853.
16. Pompili M., Di Cosimo D., Innamorati M., Lester D., Tatarelli R., Martelletti P. Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J Headache Pain 2009, 10(4):283-290.
17. Frediani F., Villani V. Migraine and depression. Neurol Sci 2007, 28(Suppl. 2):S161-S165.
18. Dilsaver S.C., Benazzi F., Oedegaard K.J., Fasmer O.B., Akiskal K.K., Akiskal H.S. Migraine headache in affectively Ill Latino adults of Mexican American origin is associated with bipolarity. Prim Care Companion J Clin Psychiatry 2009, 11(6):302-306.
19. Ortiz A., Cervantes P., Zlotnik G., et al. Cross-prevalence of migraine and bipolar disorder. Bipolar disord 2010, 12(4):397-403.
20. Silberstein S.D. Serotonin (5-HT) and migraine. Headache 1994, 34(7):408-417.
21. Hargreaves R.J., Shepheard S.L. Pathophysiology of migraine - New insights. Can J Neurol Sci 1999, 26(Suppl. 3):S12-9.
22. Mahmood T., Silverstone T. Serotonin and bipolar disorder. J Affect Disord 2001, 66(1):1-11.
23. Hamel E. Serotonin and migraine: biology and clinical implications. Cephalalgia 2007, 27(11):1293-1300.
24. Peroutka S.J. Dopamine and migraine. Neurology 1997, 49(3):650-656.
25. Emilien G., Maloteaux J.M., Geurts M., Hoogenberg K., Cragg S. Dopamine receptors - Physiological understanding to therapeutic intervention potential. Pharmacol Ther 1999, 84(2):133-156.
26. Vaccaro M., Riva C., Tremolizzo L., et al. Platelet glutamate uptake and release in migraine with and without aura. Cephalalgia 2007, 27(1):35-40.
27. Ng W.X., Lau I.Y., Graham S., Sim K. Neurobiological evidence for thalamic, hippocampal and related glutamatergic abnormalities in bipolar disorder: a review and synthesis. Neurosci Biobehav Rev 2009, 33(3):336-354.
28. Mathew N.T., Saper J.R., Silberstein S.D., et al. Migraine prophylaxis with divalproex. Arch Neurol 1995, 52(3):281-286.
29. Silberstein S.D., Wilmore L.J. Divalproex sodium: migraine treatment and monitoring. Headache 1996, 36(4):239-242.
30. Bowden C.L., Calabrese J.R., Mcelroy S.L., et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000, 57(5):481-489.
31. Bowden C.L. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000, 61(Suppl. 9):35-40.
32. Bowden C.L. Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother 2002, 3(10):1513-1519.
33. Krymchantowski A.V., Jevoux C. Quetiapine for the prevention of migraine refractory to the combination of atenolol+nortriptyline+flunarizine: an open pilot study. Arq Neuropsiquiatr 2008, 66(3B):615-618.
34. Welch K.M., Barkley G.L., Tepley N., Ramadan N.M. Central neurogenic mechanisms of migraine. Neurology 1993, 43(6 Suppl. 3):S21-S25.
35. Goadsby P.J. Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine. Cephalalgia 2002, 22(2):107-111.
36. Bigal M.E., Lipton R.B. Modifiable risk factors for migraine progression. Headache 2006, 46(9):1334-1343.
37. Brietzke E., Stabellini R., Grassis-Oliveira R., Lafer B. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectr 2011.
38. Beurel E., Michalek S.M., Jope R.S. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010, 31(1):24-31.
39. Zhang Z., Zhang Z.Y., Fauser U., Schluesener H.J. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 2008, 65(24):4055-4065.
40. Mortimer M.J., Kay J., Gawkrodger D.J., Jaron A., Barker D.C. The prevalence of headache and migraine in atopic children: an epidemiological study in general practice. Headache 1993, 33(8):427-431.
41. Terwindt G.M., Ferrari M.D., Tijhuis M., Groenen S.M., Picavet H.S., Launer L.J. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000, 55(5):624-629.
42. Chabriat H., Danchot J., Michel P., Joire J.E., Henry P. Precipitating factors of headache. A prospective study in a national control-matched survey in migraineurs and nonmigraineurs. Headache 1999, 39(5):335-338.
43. Mavromichalis I., Zaramboukas T., Giala M.M. Migraine of gastrointestinal origin. Eur J Pediatr 1995, 154(5):406-410.
44. Kemper R.H., Meijler W.J., Korf J., Ter Horst G.J. Migraine and function of the immune system: a meta-analysis of clinical literature published between 1966 and 1999. Cephalalgia 2001, 21(5):549-557.
45. Boettger M.K., Weber K., Grossmann D., et al. Spinal tumor necrosis factor alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis: a role for spinal tumor necrosis factor alpha during induction and maintenance of peripheral inflammation. Arthritis Rheum 2010, 62(5):1308-1318.
46. Schafers M., Sommer C., Geis C., Hagenacker T., Vandenabeele P., Sorkin L.S. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience 2008, 157(2):414-423.
47. Perini F., D'andrea G., Galloni E., et al. Plasma cytokine levels in migraineurs and controls. Headache 2005, 45(7):926-931.
48. Covelli V., Munno I., Pellegrino N.M., et al. In vivo administration of propranolol decreases exaggerated amounts of serum TNF-alpha in patients with migraine without aura. Possible mechanism of action. Acta Neurol (Napoli) 1992, 14(4-6):313-319.
49. Bockowski L., Sobaniec W., Zelazowska-Rutkowska B. Proinflammatory plasma cytokines in children with migraine. Pediatr Neurol 2009, 41(1):17-21.
50. Kapczinski F., Dias V.V., Kauer-Sant'anna M., et al. The potential use of biomarkers as an adjunctive tool for staging bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33(8):1366-1371.
51. Lipton R.B., Pan J. Is migraine a progressive brain disease?. JAMA 2004, 291(4):493-494.
52. Scher A.I., Stewart W.F., Ricci J.A., Lipton R.B. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003, 106(1-2):81-89.
53. Bigal M.E., Liberman J.N., Lipton R.B. Obesity and migraine: a population study. Neurology 2006, 66(4):545-550.
54. Bigal M.E., Lipton R.B. Obesity is a risk factor for transformed migraine but not chronic-tension type headache. Neurology 2006, 67:252-257.
55. Lee Y.H., Pratley R.E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep 2005, 5(1):70-75.
56. Alessi M.C., Lijnen H.R., Bastelica D., Juhan-Vague I. Adipose tissue and atherothrombosis. Pathophysiol Haemost Thromb 2003, 33(5-6):290-297.
57. Calkin C., Van De Velde C., Ruzickova M., et al. Can body mass index help predict outcome in patients with bipolar disorder?. Bipolar disord 2009, 11(6):650-656.
58. Yim CY, Soczynska JK, Kennedy SH, Woldeyohannes HO, Brietzke E, Mcintyre RS. The effect of overweight/obesity on cognitive function in euthymic individuals with bipolar disorder. Eur Psychiatry 2011, in press.
59. Craddock N., Jones I. Genet bipolar disord. J Med Genet 1999, 36(8):585-594.
60. Smoller J.W., Finn C.T. Family, twin, and adoption studies of bipolar disorder. Am J Med Genet C Semin Med Genet 2003, 123C(1):48-58.
61. Craddock N., Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006, 14(6):660-668.
62. Mcqueen M.B., Devlin B., Faraone S.V., et al. Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet 2005, 77(4):582-595.
63. Oedegaard K.J., Greenwood T.A., Lunde A., Fasmer O.B., Akiskal H.S., Kelsoe J.R. A genome-wide linkage study of bipolar disorder and co-morbid migraine: replication of migraine linkage on chromosome 4q24, and suggestion of an overlapping susceptibility region for both disorders on chromosome 20p11. J Affect Disord 2010, 122(1-2):14-26.
64. De Vries B., Frants R.R., Ferrari M.D., Van Den Maagdenberg A.M. Molecular genetics of migraine. Hum Genet 2009, 126(1):115-132.
65. Gervil M., Ulrich V., Kyvik K.O., Olesen J., Russell M.B. Migraine without aura: a population-based twin study. Ann Neurol 1999, 46(4):606-611.
66. Anttila V., Kallela M., Oswell G., et al. Trait components provide tools to dissect the genetic susceptibility of migraine. Am J Hum Genet 2006, 79(1):85-99.
67. Nyholt D.R., Laforge K.S., Kallela M., et al. A high-density association screen of 155 ion transport genes for involvement with common migraine. Hum Mol Genet 2008, 17(21):3318-3331.
68. Ghosh J., Joshi G., Pradhan S., Mittal B. Investigation of TNFA 308G>A and TNFB 252G>A polymorphisms in genetic susceptibility to migraine. J Neurol 2010, 257(6):898-904.
69. Wieser T., Pascual J., Oterino A., Soso M., Barmada M., Gardner K.L. A novel locus for familial migraine on Xp22. Headache 2010, 50(6):955-962.
70. Yilmaz I.A., Ozge A., Erdal M.E., Edgunlu T.G., Cakmak S.E., Yalin O.O. Cytokine polymorphism in patients with migraine: some suggestive clues of migraine and inflammation. Pain Med 2010, 11(4):492-497.
71. Trabace S., Brioli G., Lulli P., et al. Tumor necrosis factor gene polymorphism in migraine. Headache 2002, 42(5):341-345.
72. Rainero I., Grimaldi L.M., Salani G., et al. Association between the tumor necrosis factor-alpha -308 G/A gene polymorphism and migraine. Neurology 2004, 1:141-143.
73. Mazaheri S., Hajilooi M., Rafiei A. The G-308A promoter variant of the tumor necrosis factor-alpha gene is associated with migraine without aura. J Neurol 2006, 53(12):1589-1593.
74. Daruy-Filho L., Brietzke E., Lafer B., Grassi-Oliveira R. Childhood maltreatment and clinical outcomes of bipolar disorder. Acta Psychiatr Scand 2011, 124(6):427-434.
75. Bigal M.E., Lipton R.B., Winner P., Reed M.L., Diamond S., Stewart W.F. Migraine in adolescents: association with socioeconomic status and family history. Neurology 2007, 69(1):16-25.
76. Tietjen G.E., Brandes J.L., Peterlin B.L., et al. Childhood maltreatment and migraine (part I). Prevalence and adult revictimization: a multicenter headache clinic survey. Headache 2010, 50(1):20-31.
77. Tietjen G.E., Brandes J.L., Peterlin B.L., et al. Childhood maltreatment and migraine (part II). Emotional abuse as a risk factor for headache chronification. Headache 2010, 50(1):32-41.
78. Tietjen G.E., Brandes J.L., Peterlin B.L., et al. Childhood maltreatment and migraine (part III). Association with comorbid pain conditions. Headache 2010, 50(1):42-51.
79. Tietjen G.E., Brandes J.L., Digre K.B., et al. History of childhood maltreatment is associated with comorbid depression in women with migraine. Neurology 2007, 69(10):959-968.
80. Danese A., Moffitt T.E., Harrington H., et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med 2009, 163(12):1135-1143.
81. Heim C., Newport D.J., Mletzko T., Miller A.H., Nemeroff C.B. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008, 33(6):693-710.
82. Maes M., Lin A.H., Delmeire L., et al. Elevated serum interleukin-6 (IL-6) and IL-6 receptor concentrations in posttraumatic stress disorder following accidental man-made traumatic events. Biol Psychiatry 1999, 45(7):833-839.
83. Spivak B., Shohat B., Mester R., et al. Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. Biol Psychiatry 1997, 42(5):345-348.
84. Yehuda R., Teicher M.H., Trestman R.L., Levengood R.A., Siever L.J. Cortisol regulation in posttraumatic stress disorder and major depression: a chronobiological analysis. Biol Psychiatry 1996, 40(2):79-88.
85. Boulanger L.M. Immune proteins in brain development and synaptic plasticity. Neuron 2009, 64(1):93-109.
86. Tomoda A., Navalta C.P., Polcari A., Sadato N., Teicher M.H. Childhood sexual abuse is associated with reduced gray matter volume in visual cortex of young women. Biol Psychiatry 2009, 66(7):642-648.
87. Tomoda A., Suzuki H., Rabi K., Sheu Y.S., Polcari A., Teicher M.H. Reduced prefrontal cortical gray matter volume in young adults exposed to harsh corporal punishment. Neuroimage 2009, 47(Suppl. 2):T66-T71.
88. Choi J., Jeong B., Rohan M.L., Polcari A.M., Teicher M.H. Preliminary evidence for white matter tract abnormalities in young adults exposed to parental verbal abuse. Biol Psychiatry 2009, 65(3):227-234.
89. Grassi-Oliveira R., Ashy M., Stein L.M. Psychobiology of childhood maltreatment: effects of allostatic load?. Rev Bras Psiquiatr 2008, 30(1):60-68.